Overall (N = 1,013) | PT-INR ≤ 1.2 (N = 505) | 1.2 < PT-INR ≤ 1.4 (N = 265) | 1.4 < PT-INR ≤ 1.6 (N = 106) | 1.6 < PT-INR (N = 137) | P-value | |
---|---|---|---|---|---|---|
Patient characteristics | ||||||
Age, years | 72 (63–81) | 74 (64–82) | 70 (63–79) | 72 (62–-82) | 72 (62–79) | 0.182 |
Sex (female/male) | 391/622 | 198/307 | 100/165 | 38/68 | 55/82 | 0.887 |
Preexisting conditions | ||||||
Charlson Comorbidity Index | 1 (0–2) | 1 (0–2) | 1 (0–2) | 1 (0–3) | 2 (0–3) | 0.070 |
ADL dependent/independent | 223/779 | 119/386 | 63/201 | 17/89 | 34/103 | 0.403 |
Disease severity | ||||||
APACHE II score | 22 (17–29) | 21 (16–28) | 24 (17–31)a | 24 (18–33)a | 28 (18–33)a,b | < 0.001 |
SOFA score | 9 (6–11) | 8 (5–10) | 9 (6–12)a | 11 (7–13)a,b | 11 (7–13)a,b | < 0.001 |
SIRS score | 3 (2–4) | 3 (2–4) | 3 (3–4) | 3 (3–4) | 3 (2–3) | 0.081 |
DIC score | 4 (2–5) | 3 (2–5) | 4 (3–6)a | 5 (3–6)a,b | 5 (2–6)a | < 0.001 |
DIC, % (freq.) | 50.9 (516) | 40.4 (204) | 59.2 (157)a | 70.8 (75)a,b | 58.4 (80)a | < 0.001 |
Septic shock, % (freq.) | 62.6 (634) | 55.2 (279) | 64.9 (172)a | 78.3 (83)a,b | 73.0 (100)a | < 0.001 |
Blood culture (positive), % (freq.) | 58.2 (586) | 55.0 (275) | 61.9 (164) | 61.0 (64) | 60.6 (83) | 0.223 |
Primary site of infection, % (freq.) | < 0.001 | |||||
Lung | 31.3 (317) | 35.0 (177) | 31.7 (84) | 21.7 (23) | 24.1 (33) | |
Abdomen | 26.8 (271) | 22.8 (115) | 28.7 (76) | 43.4 (46) | 24.8 (34) | |
Urinary tract | 18.6 (188) | 20.6 (104) | 14.0 (37) | 16.0 (17) | 21.9 (30) | |
Skin/soft tissue | 7.7 (98) | 8.5 (43) | 14.0 (37) | 5.7 (6) | 8.8 (12) | |
Intravenous catheter | 1.7 (17) | 2.0 (10) | 0.8 (2) | 2.8 (3) | 1.5 (2) | |
Bone/joint | 1.7 (17) | 1.8 (9) | 0.8 (2) | 0.9 (1) | 3.6 (5) | |
CNS | 1.9 (19) | 2.4 (12) | 2.3 (6) | 0.9 (1) | 0 (0) | |
Endocardium | 1.4 (14) | 1.6 (8) | 0.8 (2) | 0.9 (1) | 2.2 (3) | |
Implant device | 0.6 (6) | 0.6 (3) | 0 (0) | 0.9 (1) | 1.5 (2) | |
Wound | 1.2 (12) | 1.2 (6) | 1.5 (4) | 0.9 (1) | 0.7 (1) | |
Others | 5.3 (54) | 3.6 (18) | 5.7 (15) | 5.7 (6) | 10.9 (15) | |
Therapeutic interventions | ||||||
Mechanical ventilation, % (freq) | 42.4 (422) | 38.4 (191) | 45.8 (120) | 54.9 (56)a | 40.7 (55) | 0.026 |
PMX-DHP, % (freq) | 9.1 (89) | 7.4 (37) | 8.3 (21)a | 15.6 (15)a,b | 12.0 (16) | < 0.001 |
IVIg, % (freq) | 20.5 (201) | 13.5 (67) | 26.1 (66)a | 30.5 (29)a | 29.3 (39)a | < 0.001 |
Antithrombin, % (freq) | 22.2 (218) | 14.3 (71) | 25.3 (64)a | 38.9 (37)a,b | 32.6 (43)a | < 0.001 |
rTM, % (freq) | 30.4 (228) | 21.1 (87) | 38.3 (70)a | 61.0 (36)a,b | 36.8 (35)a | < 0.001 |
Protease inhibitor, % (freq) | 8.1 (79) | 7.2 (36) | 8.7 (22)a | 11.6 (11)a | 7.5 (10)a | 0.001 |
CRRT, % (freq) | 27.7 (271) | 22.3 (111) | 26.6 (67)a | 41.7 (40)a,b | 39.8 (53)a | < 0.001 |
Corticosteroids, % (freq) | 28.9 (296) | 24.3 (121) | 30.8 (78)a | 40.0 (38)a,b | 45.0 (59)a | < 0.001 |
Noradrenaline, % (freq) | 66.1 (649) | 58.7 (294) | 70.8 (179)a | 78.1 (75)a | 76.5 (101)a | < 0.001 |
Enteral nutrition, % (freq) | 49.4 (482) | 45.5 (235) | 52.2 (131)a | 45.3 (43)a | 55.3 (73)c | < 0.001 |